Biomedical subjects

A Bonnefond

Publications and source records attributed to A Bonnefond.

At least 19 recordsLinked to original sources

PubMed1987

Development of gastric argyrophil carcinoid tumors in a case of Zollinger-Ellison syndrome with primary hyperparathyroidism during long-term antisecretory treatment.

Fundic argyrophil carcinoid tumors developed in the course of a 5-year continuous treatment with high dosages of H2-antagonists in a well-documented case of Zollinger-Ellison syndrome with primary hyperparathyroidism, high basal acid output, and serum gastrin. Approximately 100 small polyps were disseminated throughout the gastric fundus exclusively, leading to total gastrectomy. Metastatic carcinoid in a lymph node and pancreatic gastrinomas also were found at surgery. Gastric endocrine cell proliferation varied from simple argyrophil cell hyperplasia to carcinoid tumors eroding the surface and infiltrating the submucosa. Ultrastructural studies showed that the tumoral proliferation was heterogeneous, and included tumors composed of enterochromaffin (EC) and typical enterochromaffin-like (EC-L) cells, and tumors in which a majority of cells exhibited dense round granules resembling those of A-like or D1/P endocrine cell types. The risk of developing gastric fundic carcinoid tumors in ZES patients submitted to long-term antisecretory treatment should be given increased attention.

Carcinoid Tumor↗

PubMed1986

[Campylobacter fetus ssp. fetus endocarditis].

Explore the source record for details and available documents.

Campylobacter Infections↗

PubMed1985

[Maintenance therapy of ulcer disease. Comparative multicenter study of sucralfate, cimetidine and a placebo].

Relapse rates were studied in one hundred patients in a multicentric, randomized trial during and after maintenance therapy comparing sucralfate, cimetidine and placebo. These patients were previously treated by cimetidine for peptic ulcer and were considered cured after endoscopic examination. Outpatients were randomly assigned to a 6 month maintenance treatment with either cimetidine (600 mg daily), sucralfate (300 mg daily) or a placebo. All patients underwent endoscopic evaluation after 3 and 6 months of therapy. A clinical évaluation was performed 6 months after all treatment had ceased. Clinical and endoscopic results proved the significant superiority of both sucralfate and cimetidine over the placebo. Remission rates with sucralfate were respectively 80,4 p. 100 after 6 months and 68,5 p. 100 after 12 months. These results were slightly superior to those observed with cimetidine (69,3 p. 100 and 61,3 p. 100). However, this difference is not statistically significant. Results for the placebo group were 47,9 p. 100 and 37,7 p. 100. Sucralfate is an effective medication in preventing the recurrence of peptic ulcer. Its pharmacological action, its few side effects and its effectiveness seem to make this medication very interesting in treating the ulcerous disease.

Aluminum↗

PubMed1984

[Lingual necrosis disclosing Horton's disease. Apropos of a case and a résumé and analysis of cases found in the medical literature].

The authors mention an observation of lingual necrosis revealing a Horton disease. The set of the usual aspects of the disease was not comprehensive and the inflammatory syndrom was rather weak; nevertheless the diagnosis of a giant cell panarteritis was admitted and a strong cortico-therapy quickly set up which greatly improved the patient. After a brief recall of the main clinical and biological signes of a Horton temporal arteritis, the circumstances, symptomatology evolution and treatment of this particular form of the disease are reviewed through 22 observations found in medical literature.

Aged↗

PubMed1979